790667-49-1

Basic information

• Product Name: 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2S)-(9CI)
• Synonyms: tert-butyl (2S)-2-methyl-4-oxopiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 2-methyl-4-oxo-, 1,1-dimethylethyl ester, (2S)-;(S)-tert-Butyl 2-methyl-4-oxopiperidine-1-carboxylate;tert-butyl(S)-2-methyl-4-oxopiperidine-1-carboxylate;1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2S)-(9CI);(2S)-2-Methyl-4-oxo-piper...;(2S)-2-Methyl-4-oxo-piperidine-1-carboxylic acid tert-butyl ester;1-N-boc-2(S)-Methyl-piperidin-4-one
• CAS NO: 790667-49-1
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.28
• Product Categories: METHYL
• Mol File: 790667-49-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 298.8±33.0 °C(Predicted)
• Appearance: /
• Density: 1.060±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.52±0.40(Predicted)
• CAS DataBase Reference: 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2S)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2S)-(9CI)(790667-49-1)
• EPA Substance Registry System: 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2S)-(9CI)(790667-49-1)

Safety Data

• Hazardous Substances Data: 790667-49-1(Hazardous Substances Data)

Usage

General Description

1-Piperidinecarboxylic acid, 2-methyl-4-oxo-, 1,1-dimethylethyl ester, (2S)-(9CI) is a chemical compound with the molecular formula C11H19NO3. It is a piperidine derivative and ester of 2-methyl-4-oxo-1-piperidinecarboxylic acid. 1-Piperidinecarboxylicacid,2-methyl-4-oxo-,1,1-dimethylethylester,(2S)-(9CI) is often used as an intermediate in organic synthesis, and it has potential applications in the pharmaceutical industry. It may also have some biological activity, although further research is needed to fully understand its properties and potential uses.

Upstream product

• 71322-99-1 2-methyl-4-oxopiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 921599-74-8 benzyl (2S)-2-methyl-4-oxopiperidine-1-carboxylate 
• 10575-36-7 (1E,4E)-hexa-1,4-dien-3-one 
• 190906-92-4 tert-butyl 2-methyl-4-oxopiperidine-1-carboxylate 
• 790667-45-7 (S)-2-methylpiperidin-4-one hydrochloride 
• 89467-36-7 (S)-2-methyl-1-((S)-1-phenyl-ethyl)piperidin-4-one 

Downstream Products

• 152491-46-8 (2S)-tert-butyl 4-hydroxy-2-methylpiperidine-1-carboxylate 
• 790667-99-1 tert-butyl (2S,4S)-4-hydroxy-2-methyl-piperidine-1-carboxylate 

Relevant articles and documents

Spiropiperidine Sultam and Lactam Templates: Diastereoselective Overman Rearrangement and Metathesis followed by NH Arylation

We report the diastereoselective synthesis of novel spiropiperidine templates for use in SAR studies of β-secretase (BACE) inhibitors and also as versatile ligands for other receptor types. The overall synthetic approach stems from chiral starting material benzyl (S)-2-methyl-4-oxopiperidine-1-carboxylate and employs an Overman rearrangement to control the stereochemistry at the quaternary center. This process is followed by a Grubbs metathesis to close a five-membered top ring to form an α,β-unsaturated lactam or an α,β-unsaturated sultam. We also demonstrate that this chemistry can accommodate additional substituents on the lactam/sultam ring and allows late stage sequential functionalization of the amine and amide nitrogens to rapidly produce diverse analogues.

Novel Sultam Compounds

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

MCH antagonists for the treatment of obesity

The present invention discloses methods of using antagonists for melanin-concentrating hormone (MCH), to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes, as well as novel compounds which are antagonists for melanin-concentrating hormone (MCH). In other aspects, the invention is directed to pharmaceutical compositions comprising such MCH antagonists as well as methods for preparing such compounds. Compounds of the invention generally have the structure: where the substituents are as defined herein.